The reduction of the levels of circulating T lymphocytes in urological neoplasias seems obvious. The existence of a link between the different, neoplastic, bladder and prostate processes, as well as the degree of malignancy, prognosis and therapeutic response has still to be established, according to the immunitary state of the patients. The constant developing and refining of the immunological technology will no doubt serve to resolve these problems.